SAREPTA THERAPEUTICS, INC. Employee Benefits and Share-based Compensation
SAREPTA THERAPEUTICS, INC. (SRPT) reported Employee Benefits and Share-based Compensation of $26.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2024-02-28
- SAREPTA THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2023-12-31 was $8.60M.
- SAREPTA THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2023-09-30 was $10.30M.
- SAREPTA THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2023-06-30 was -$70.90M.
- SAREPTA THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2023-03-31 was $78.30M, a 2425.81% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. employee benefits and share-based compensation for fiscal 2023 was $26.30M, a 748.39% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. employee benefits and share-based compensation for fiscal 2022 was $3.10M.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 12 month |
|---|---|---|---|---|
| 2023-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $18.90M derived: sum of 2 quarters · filed 2024-02-28 | -$52.00M derived: sum of 3 quarters · filed 2024-02-28 | $26.30M 10-K · filed 2024-02-28 |
| 2023-09-30 | $10.30M 10-Q · filed 2023-11-01 | -$60.60M derived: sum of 2 quarters · filed 2023-11-01 | $17.70M 10-Q · filed 2023-11-01 | $17.70M derived: sum of 4 quarters · filed 2023-11-01 |
| 2023-06-30 | -$70.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $7.40M 10-Q · filed 2023-08-02 | $7.40M derived: sum of 3 quarters · filed 2023-08-02 | $7.40M derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | $78.30M 10-Q · filed 2023-05-02 | $78.30M derived: sum of 2 quarters · filed 2023-05-02 | $78.30M derived: sum of 3 quarters · filed 2023-05-02 | $78.30M derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $3.10M 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $3.10M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $3.10M 10-Q · filed 2022-08-02 | ||
| 2022-03-31 | $3.10M 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |